早期试验以确定轻度至中期患者的Ratutrelvir的安全有效剂量-19
一项多中心,开放标签,随机2A研究,以评估无院症状的成年参与者轻度至中度COVID-19
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
研究概览
详细说明
This is a multicenter, open-label, randomized Phase 2a study to evaluate the safety and efficacy of 83-0060 (Ratutrelvir) and Nirmatrelvir-Ritonavir (Paxlovid) in non-hospitalized symptomatic adult participants with mild to moderate COVID-19.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Tashkent
-
Tashkent、Tashkent、乌兹别克斯坦、100194
- Research Institute of Virology
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Confirmed SARS-CoV-2 infection for 120 h prior to randomization.
- Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization.
- At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the severity score of 1 or higher according to the following scoring system for the assessment of severity of:
Exclusion Criteria:
Medical Conditions:
-
History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.
-
Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.
-
Known medical history of active liver disease .
-
Receiving dialysis or history of moderate to severe renal impairment.
-
Compromised immune system.
-
Acute episode of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease within 30 days before screening.
-
Suspected or confirmed concurrent active systemic infection..
Prior/Concomitant Therapy:
-
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine within 4 months of screening and during the participation in the study.
-
Concomitant use of any medications or substances that are strong inducers of CYP3A4
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Ratutrelvir(83-0060)非随机
|
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
|
实验性的:Ratutrelvir(83-0060)
|
83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
|
有源比较器:Paxlovid
Standard of care |
Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety based on adverse events incidence
大体时间:28 days
|
Adverse events incidence will be described using descriptive statistics methods |
28 days
|
|
Safety based on adverse events severity
大体时间:28 days
|
Adverse events severity will be assessed by current version of CTCAE |
28 days
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
基于时间(天)的疗效,以持续恢复所有有针对性的COVID-19的标志/症状28
大体时间:28天
|
28天
|
|
基于在第28天持续恢复每种目标共同症状的时间的时间。
大体时间:28天
|
28天
|
|
基于最大血浆浓度(CMAX)的83-0060的PK特性
大体时间:11天
|
11天
|
|
基于浓度时间曲线的面积为83-0060的PK特性从0到上次可量化浓度的时间(Auclast)
大体时间:11天
|
11天
|
|
基于CMAX的时间(TMAX)的83-0060的PK特性
大体时间:11天
|
11天
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.